Wells Fargo & Company restated their buy rating on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a research report report published on Tuesday morning.

Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Jazz Pharmaceuticals PLC from a hold rating to a buy rating and set a $174.00 price target for the company in a research report on Monday, May 15th. Vetr upgraded shares of Jazz Pharmaceuticals PLC from a hold rating to a buy rating and set a $151.11 price target for the company in a research report on Tuesday, June 6th. Cantor Fitzgerald reiterated a buy rating and set a $197.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, June 27th. Royal Bank Of Canada set a $210.00 price target on shares of Jazz Pharmaceuticals PLC and gave the stock a buy rating in a research report on Tuesday, June 27th. Finally, Deutsche Bank AG reiterated a buy rating and set a $176.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have given a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $180.96.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 1.20% during midday trading on Tuesday, hitting $147.57. 444,049 shares of the stock traded hands. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75. The company has a 50-day moving average of $151.04 and a 200-day moving average of $149.06. The stock has a market cap of $8.86 billion, a PE ratio of 22.73 and a beta of 1.13.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The business had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. During the same quarter in the prior year, the firm earned $2.67 EPS. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post $10.89 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/02/jazz-pharmaceuticals-plc-jazz-given-buy-rating-at-wells-fargo-company.html.

In other Jazz Pharmaceuticals PLC news, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $150.65, for a total value of $30,130.00. Following the transaction, the executive vice president now owns 22,223 shares of the company’s stock, valued at $3,347,894.95. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Paul Treacy sold 1,304 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $143.32, for a total transaction of $186,889.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,917 shares of company stock worth $1,223,227. Insiders own 4.30% of the company’s stock.

Several hedge funds have recently bought and sold shares of JAZZ. OppenheimerFunds Inc. increased its stake in Jazz Pharmaceuticals PLC by 54.1% in the first quarter. OppenheimerFunds Inc. now owns 150,840 shares of the specialty pharmaceutical company’s stock worth $21,891,000 after buying an additional 52,960 shares during the period. UBS Group AG increased its stake in Jazz Pharmaceuticals PLC by 17.3% in the first quarter. UBS Group AG now owns 338,433 shares of the specialty pharmaceutical company’s stock worth $49,116,000 after buying an additional 50,032 shares during the period. HighTower Advisors LLC acquired a new stake in Jazz Pharmaceuticals PLC during the first quarter worth about $347,000. Somerset Trust Co increased its stake in Jazz Pharmaceuticals PLC by 0.4% in the second quarter. Somerset Trust Co now owns 3,194 shares of the specialty pharmaceutical company’s stock worth $497,000 after buying an additional 14 shares during the period. Finally, Pinnacle Associates Ltd. acquired a new stake in Jazz Pharmaceuticals PLC during the first quarter worth about $235,000. Institutional investors own 88.24% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.